First Line Medical Treatment of Metastatic Renal Cell Carcinoma: A Podcast on Choosing Wisely and Managing Safely

With recent advancements in medical treatments for metastatic renal cell carcinoma (mRCC), increased treatment efficiency may also come with increased toxicity. In this podcast, authors discuss the appropriate management of the adverse events that result from drug toxicity in order to achieve optimal oncological outcomes for their patients whilst still maintaining their quality of life. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-023-02571-5. All conflicts of interest can be found online. This podcast has been developed through an educational grant from Eisai. The authors were selected by the journal, and the content of the podcast was developed independently by the authors and the journal Editor. The Rapid Service and Open Access Fees were also funded by the unrestricted educational grant from Eisai. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.   This podcast in intended for medical professionals.